About the Authors

Kasmintan A. Schrader, Janine Senz, Alireza Heravi-Moussavi, Nataliya Melnyk, Clara Salamanca, Sarah Maines-Bandiera, David G. Huntsman
Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, British Columbia, Canada

Kasmintan A. Schrader, Janine Senz, Nataliya Melnyk, John Monahan
Centre for Translational and Applied Genomics, British Columbia Cancer Agency, Vancouver, British Columbia, Canada

Bella Gorbatcheva, David G. Huntsman
Novartis Institute for Biomedical Research, Cambridge, Massachusetts, United States of America

Susanna L. Cooke, James D. Brenton
Cancer Research, Cambridge Research Institute, Cambridge, United Kingdom

Peter Leung
Department of Obstetrics and Gynecology, University of British Columbia, Child and Family Research Institute, Vancouver, British Columbia, Canada

C. Blake Gilks, David G. Huntsman
Genetic Pathology and Evaluation Centre, Vancouver General Hospital, Vancouver, British Columbia, Canada

Corresponding Author

dhuntsma@bccancer.bc.ca

Competing Interests

The British Columbia Cancer Agency is the holder of a provisional patent on the use of the FOXL2 mutation as a potential diagnostic and therapeutic target. Bella Gorbatcheva and John Monahan are both employees of the Novartis Institutes for BioMedical Research. These competing interests do not impact the sharing of data related to this publication.

Author Contributions

Conceived and designed the experiments: KAS BG JDB CBG JM DH. Performed the experiments: BG JS AHM NM CS SMB SLC JM. Analyzed the data: KAS BG JS AHM NM PL JDB CBG JM DH. Contributed reagents/materials/analysis tools: CS SMB SLC PL JDB CBG JM. Wrote the paper: KAS BG JDB JM DH.